FDA-Approved Neuromodulation Treatment for Women with Bladder Dysfunction

Thursday, April 10, 2003

Mayo Clinic in Scottsdale has a long history of providing multi-disciplinary care for female patients with bladder dysfunction. Neuromodulation, or sacral nerve stimulation, has been approved by the FDA for the management of intractable bladder over-activity, urinary frequency and non-obstructive urinary retention. Patients with bladder over-activity refractory to all common management modalities demonstrate a 60-70% response rate to neuromodulation. Patients who experience uninhibited bladder contractions with concomitant urinary retention may see each of the conditions significantly improved following neuromodulation due to its affects on the sensory nerves.

Dr. Jeffrey L. Cornella developed the multi-disciplinary program and provides services in association with clinicians in physical therapy, occupational therapy, patient education, neurology, gastroenterology, colorectal surgery and urology. Dr. Cornella directs the division of Reconstructive Surgery and the three-year fellowship program in urogynecology and pelvic floor medicine. His areas of expertise include:

• Evaluation and management of female urinary incontinence.
• Evaluation and management of pelvic organ prolapse.
• Evaluation and management of patients with fecal incontinence secondary to obstetrical injury.
• Minimally invasive surgery for benign pelvic conditions.
• Minimally invasive hysterectomy for the large uterus.
• Genitourinary fistula.

###

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com is available as a resource for your health stories.